Articles from Pretzel Therapeutics, Inc.
Pretzel Therapeutics Receives UK Regulatory Authorization to Advance PX578 Into Clinical Development in Patients for the Treatment of POLG-Mediated Primary Mitochondrial Disorders
Pretzel Therapeutics, Inc., a clinical-stage biotechnology company advancing a new class of medicines designed to restore mitochondrial function, improve cellular energetics and impede disease progression across a range of neurological and rare diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the company’s clinical trial application for PX578, the company’s lead therapeutic candidate being developed for patients with POLG-mediated mitochondrial disorders (POLG disease), a rare, progressive genetic disorder caused by mutations in the POLG gene causing a depletion of mitochondrial DNA.
By Pretzel Therapeutics, Inc. · Via Business Wire · October 30, 2026
Pretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial Disorders
Pretzel Therapeutics, Inc., a clinical-stage biotechnology company advancing a new class of medicines designed to restore mitochondrial function, improve cellular energetics and impede disease progression across a range of neurological and rare diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PX578 for the treatment of POLG-mediated primary mitochondrial disorders (POLG disease), a rare, progressive genetic condition for which there are currently no approved disease-modifying treatments.
By Pretzel Therapeutics, Inc. · Via Business Wire · September 22, 2026
Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND
Pretzel Therapeutics, Inc., a clinical-stage biotechnology company advancing a new class of medicines designed to restore mitochondrial function, improve cellular energetics and impede disease progression across a range of neurological and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a first-in-patient clinical trial of PX578, the Company’s lead therapeutic candidate. The Phase 2 study, POLARIS (POLg Activation and Recovery In Subjects), will evaluate PX578 in adult patients with POLG-mediated primary mitochondrial disease (POLG disease), a rare, progressive genetic disorder caused by mutations in the POLG gene causing a depletion of mitochondrial DNA. This mitochondrial DNA depletion syndrome results in mitochondrial dysfunction and a range of debilitating neurological and systemic manifestations. There are currently no approved disease-modifying treatments for this condition. POLARIS will build on recent success with a Phase 1 healthy volunteer study with PX578 conducted in New Zealand.
By Pretzel Therapeutics, Inc. · Via Business Wire · August 25, 2026